Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05013099 · ClinicalTrials.gov registry record · Phase 2

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

A Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by ImaginAb.

Active
Registry status
Phase 2
Development phase
70
Enrollment target
16
Study locations

NCT05013099 is a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma that is active but no longer recruiting, run by ImaginAb. The registered enrollment target is 70 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 16 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05013099, a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by ImaginAb.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
70 participants
Enrollment target
16
Study locations

Study Summary

The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell lung cancer tumors to immuno-oncology therapy.

Conditions Studied

Non-Small Cell Lung Cancer Melanoma Renal Cell Carcinoma Merkel Cell Carcinoma, Unspecified

Interventions

  • BIOLOGICAL zirconium Zr 89 crefmirlimab berdoxam

Study Locations (16)

Other

  • University Hospitals Leuven - Leuven
  • Leiden University Medical Center - Leiden
  • Lausanne University Hospital - Lausanne
  • Northern Centre for Cancer Care and Newcastle University - Newcastle upon Tyne

California

  • City of Hope - Duarte
  • Providence Saint John's Cancer Institute - Santa Monica

Victoria

  • Olivia Newton-John Cancer Research Insititute - Heidelberg
  • Peter MacCallum Cancer Centre - Melbourne

Arkansas

  • CARTI Cancer Center - Little Rock

New York

  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • UT Southwestern Medical Center - Dallas

Washington

  • University of Washington - Seattle

New South Wales

  • Macquarie University Hospital - Macquarie Park

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2021-12-09
Est. Completion 2025-07
Phase Phase 2

Sponsor

ImaginAb

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05013099

The ClinicalTrials.gov registry entry for NCT05013099 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The listed sponsor is ImaginAb, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which zirconium Zr 89 crefmirlimab berdoxam is the first listed.

NCT05013099 reports 16 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Victoria.

Frequently Asked Questions

What is clinical trial NCT05013099 about?

NCT05013099 is a clinical study titled "Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies". The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell l...

What is the current status of trial NCT05013099?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2021-12-09. Estimated completion is 2025-07.

What conditions does trial NCT05013099 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Merkel Cell Carcinoma, Unspecified.

What interventions are being tested in trial NCT05013099?

The interventions under investigation include: zirconium Zr 89 crefmirlimab berdoxam (BIOLOGICAL).

Who is sponsoring clinical trial NCT05013099?

This trial is sponsored by ImaginAb, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05013099 being conducted?

This trial has 16 study locations across Arkansas, California, New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Melanoma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.